Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Benson

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Medicine|February 24, 2025
Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority studyIndira Brar, Peter J Ruane, Mezgebe Berhe, et al.
Frontiers in Medicine|March 27, 2023
Spatial transcriptomic profiling of coronary endothelial cells in SARS-CoV-2 myocarditisCamilla Margaroli, Paul Benson, Maria G Gastanadui, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2022
Spatial transcriptomic profiling of coronary endothelial cells in SARS-CoV-2 myocarditisCamilla Margaroli, Paul Benson, Maria G Gastanadui, et al.
AIDS (London, England)|May 26, 2018
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamidePaul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 13, 2016
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected AdultsJoel Gallant, Jason Brunetta, Gordon Crofoot, et al.
Infectious Diseases and Therapy|April 3, 2024
Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup AnalysesPaul Benson, Jennifer Kuretski, Cynthia Donovan, et al.
Cell Reports. Medicine|March 29, 2021
Spatial mapping of SARS-CoV-2 and H1N1 lung injury identifies differential transcriptional signaturesCamilla Margaroli, Paul Benson, Nirmal S Sharma, et al.
AIDS (London, England)|March 7, 2025
Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruptionGraeme Moyle, Joshua Gruber, Megan Dunbar, et al.
The Lancet. HIV|February 22, 2017
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trialPaul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
AIDS Patient Care and Stds|June 5, 2026
People with HIV Continuing on Complex Regimens in the Era of Treatment Optimization: Characteristics and OutcomesPaul E Sax, Keith J Dunn, Janna Radtchenko, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Medicine|February 24, 2025
Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority studyIndira Brar, Peter J Ruane, Mezgebe Berhe, et al.
Frontiers in Medicine|March 27, 2023
Spatial transcriptomic profiling of coronary endothelial cells in SARS-CoV-2 myocarditisCamilla Margaroli, Paul Benson, Maria G Gastanadui, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2022
Spatial transcriptomic profiling of coronary endothelial cells in SARS-CoV-2 myocarditisCamilla Margaroli, Paul Benson, Maria G Gastanadui, et al.
AIDS (London, England)|May 26, 2018
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamidePaul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 13, 2016
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected AdultsJoel Gallant, Jason Brunetta, Gordon Crofoot, et al.
Infectious Diseases and Therapy|April 3, 2024
Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup AnalysesPaul Benson, Jennifer Kuretski, Cynthia Donovan, et al.
Cell Reports. Medicine|March 29, 2021
Spatial mapping of SARS-CoV-2 and H1N1 lung injury identifies differential transcriptional signaturesCamilla Margaroli, Paul Benson, Nirmal S Sharma, et al.
AIDS (London, England)|March 7, 2025
Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruptionGraeme Moyle, Joshua Gruber, Megan Dunbar, et al.
The Lancet. HIV|February 22, 2017
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trialPaul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
AIDS Patient Care and Stds|June 5, 2026
People with HIV Continuing on Complex Regimens in the Era of Treatment Optimization: Characteristics and OutcomesPaul E Sax, Keith J Dunn, Janna Radtchenko, et al.
Pageof 4